Another problem faced by the clinician is that the Food and Drug Administration (FDA) ascertains efficacy on the basis of nonrepresentative psychiatric populations. For example, the FDA will not include in a study sample patients with schizophrenia who have drug and/or alcohol problems, let alone a history of head injury. The clinician, then, is to use data based on patients without these disorders as evidence for the treatment of patients with schizophrenia in the real world, who in fact have more comorbid disorders. All the more reason why a volume such as this can be useful.